Importantly, CIS requires the combined action of TNF and IFN-γ, as immune therapies of cancers in the absence of either IFN-γ, of Stat1- or of Tnfr1-signalling strongly accelerate the transformation and growth of cancer cells19,25. Here, TNFRSF1A is linked to in situ carcinoma.